On the stock market since 2013, it operates in the world of health and science. It has 491 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 37% a year on average.
Sales run at $408.1M a year. A small number, but proof the product has real buyers.
It pays out $0.38 per share each year — regular cash for whoever holds the stock.
A loss of $93.8M against $408.1M in annual sales.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
On our five-subject report card, MAYNF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MAYNF is a high-risk stock — not yet profitable, and its future rides on its product catching on.